Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate init ...

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Charcot-Marie-Tooth Sorbitol Dehydrogenase ...

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

Q1 2025 Management View CEO Dror Bashan highlighted the company’s focus on advancing its clinical pipeline, particularly ...

DRP® Platform Expansion Beyond Small Molecules: At AACR 2025, Allarity presented a novel DRP® for daratumumab in multiple myeloma, marking the Company's first DRP developed for a targeted antibody ...

Protalix BioTherapeutics, Inc. (AMEX: PLX) Q1 2025 Earnings Call Transcript May 9, 2025 Protalix BioTherapeutics, Inc. misses ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Cumberland Pharmaceuticals, Inc. ( NASDAQ: CPIX) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, ...